CurrentCignaPolicy IP0315

Hereditary Angioedema - C1 Esterase Inhibitors (Intravenous)

Cigna coverage policy defining medical necessity, prior authorization requirements, diagnostic and dosing criteria for IV C1-esterase inhibitors for hereditary angioedema (HAE) acute treatment and prophylaxis across Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyHereditary Angioedema - C1 Esterase Inhibitors (Intravenous)

Policy CodePolicy IP0315

Change TypeClarified wording and documentation

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain prior authorization and provide baseline laboratory documentation (C1‑INH functional level, C1‑INH antigen where applicable, serum C4) and evidence of clinical response; ensure prescriptions are by or in consultation with an allergist/immunologist or HAE specialist.

SourceLink

POLICY UPDATE CHANGES

Updated policy title to 'Hereditary Angioedema - C1 Esterase Inhibitors (Intravenous)' and revised documentation and specialist prescriber language.

3drugs addressed (Berinert, Cinryze, Ruconest)

3HCPCS codes listed

1typical approval duration (years)

20acute dosing (IU/kg)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria — IV C1 Esterase Inhibitors

Medically Necessary — Berinert or Cinryze (Prophylaxis)

Approve Berinert or Cinryze for 1 year if the patient meets ONE of the following (initial therapy or continuation):

ANY of the following

Initial therapy
- Patient has HAE type I or type II as confirmed by diagnostic criteria
  HAE with normal C1-INH (type III) does NOT satisfy this requirement
- Diagnostic criteria for HAE type I/II
  - Low functional C1-INH protein (< 50% of normal) at baseline< 50% of normal
    [documentation required]
  - Lower than normal serum C4 level at baseline
    [documentation required]
- Medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders
Continuation (patient currently receiving Berinert or Cinryze prophylaxis)
- Patient has a diagnosis of HAE type I or type II
  [documentation required]
- According to the prescriber, patient has had a favorable clinical response since initiating prophylactic therapy (e.g., decreased attack frequency/severity/duration)
- Medication is prescribed by or in consultation with an allergist/immunologist or an HAE specialist

(operational note): Approvals provided for 1 year. Documentation (chart notes, lab records) required where indicated; prior authorization required; specialists should prescribe or consult.

Medically Necessary — Berinert or Cinryze (Treatment of Acute Attacks)

Approve Berinert or Cinryze for 1 year if the patient meets ONE of the following (initial therapy or treated previous attacks):

ANY of the following

Initial therapy
- Diagnostic confirmation
  - Patient has HAE type I or type II
    HAE with normal C1-INH does NOT satisfy this requirement
  - Low functional C1-INH protein (< 50% of normal) at baseline< 50% of normal
    [documentation required]
  - Lower than normal serum C4 at baseline
    [documentation required]

Medically Necessary — Ruconest (Treatment of Acute Attacks)

Approve Ruconest for 1 year if patient meets ONE of the following (initial therapy or treated previous attacks):

ANY of the following

Initial therapy
- Diagnostic confirmation
  - Patient has HAE type I or type II
    HAE with normal C1-INH does NOT satisfy this requirement
  - Low functional C1-INH protein (< 50% of normal) at baseline< 50% of normal
    [documentation required]
  - Lower than normal serum C4 at baseline
    [documentation required]

Medically Necessary — HAE with Normal C1-INH (Other Uses with Supportive Evidence)

Berinert or Cinryze may be approved for treatment of acute attacks of HAE with normal C1-INH (HAE-nC1INH / type III) for 1 year when initial or prior-response criteria met:

ANY of the following

Initial therapy for HAE-nC1INH
- Laboratory criteria (both)
  - Normal C1-INH protein level and/or functional activity
    [documentation required]
  - Normal serum C4 level
    [documentation required]
- Recurrent angioedema attacks are not responsive to high-dose oral H1 antihistamine therapy
  High-dose = up to 4x FDA-approved dose; trial documented

Not Medically Necessary / Not Covered

IV C1-INH products are not medically necessary for uses other than those specified above.

ALL of the following

Ruconest for prophylaxis of HAE attacks (not FDA-approved and evidence insufficient)
This specific exclusion does not apply to Berinert or Cinryze
Any other uses not described in the policy
List may not be all-inclusive

Operational note: Requests for IV C1-INH for non-specified indications will be considered not medically necessary; prior authorization denials likely for these uses.

Relevant HCPCS Codes

HCPCS codes — medically necessary when criteria metHCPCSCovered

J0596	Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units
J0597	Injection, C1 esterase inhibitor (human), Berinert, 10 units
J0598	Injection, C1 esterase inhibitor (human), Cinryze, 10 units

What Providers Must Do

Prior Authorization

Prior authorization required

Prior Authorization is required for coverage of Berinert, Cinryze, and Ruconest. Approvals are provided for the durations noted in the policy (typically 1 year). Requests for doses outside the dosing established in the policy will be considered on a case‑by‑case basis by a clinician.

Affected HCPCS codes: J0596 (Ruconest), J0597 (Berinert), J0598 (Cinryze)

Documentation Required

Documentation of diagnostic testing and clinical response

Provide baseline laboratory documentation of diagnostic testing (C1‑INH functional level; C1‑INH antigen where applicable; serum C4) and supply evidence of clinical response for continuation approvals. Acceptable documentation includes chart notes, laboratory records, and prescription claims that include patient‑specific identifying information.

Documentation required where noted in criteria (e.g., low functional C1‑INH <50% and low serum C4)
Evidence of favorable clinical response may include decreased attack frequency, severity, or duration

Prior Authorization

Specialist prescribing requirement

The medication must be prescribed by, or in consultation with, an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders; this specialist requirement applies to initial and continuation approvals.

Specialist involvement is required because of the specialized skills for evaluation, diagnosis, monitoring adverse events, and long‑term efficacy

Denial Risk

Denial risk for non-specified indications

Requests for IV C1‑INH for indications not specified as medically necessary in the policy will be considered not medically necessary; specifically, Ruconest for prophylaxis of HAE attacks is listed as not covered.

The 'Conditions Not Covered' section names Ruconest for prophylaxis (not FDA‑approved) as not medically necessary

Clinical Thresholds and Dosing Limits

Key thresholds and dosing limits

Functional C1-INH< 50% of normal (diagnostic threshold for HAE type I/II)

Berinert/Cinryze prophylaxis maximum (age ≥12)Up to 2,500 units (not exceeding 100 units/kg), IV, no more frequently than twice weekly with doses separated by at least 3 days

Berinert/Cinryze prophylaxis maximum (age <12)Up to 1,000 units, IV, no more frequently than twice weekly with doses separated by at least 3 days

Berinert/Cinryze acute dosing20 IU/kg, IV, administered no more frequently than once daily

Ruconest dosingUp to 4,200 units (not exceeding 50 units/kg), IV, administered no more frequently than twice daily

Clinical Background

This policy addresses intravenous C1-esterase inhibitor (C1-INH) replacement therapies used in hereditary angioedema (HAE). Berinert and Cinryze are human plasma-derived C1-INH products, while Ruconest is a recombinant C1-INH purified from the milk of transgenic rabbits. These agents are indicated for on‑demand treatment of acute HAE attacks (Berinert, Ruconest) and for routine long‑term prophylaxis in select patients (Cinryze); off‑label and literature‑reported uses include cross‑use of Berinert for prophylaxis and Cinryze for acute treatment in some cases.

Diagnosis of HAE due to C1‑INH deficiency (HAE type I or II) is biochemical: patients typically have a low serum C4 and low C1‑INH functional or antigenic levels. The policy uses a diagnostic threshold of C1‑INH functional activity < 50% of normal to confirm HAE type I/II. By contrast, HAE with normal C1‑INH (HAE‑nC1INH, formerly type III) is characterized by normal C4 and normal C1‑INH levels/function and often requires genetic testing or a compatible family history plus lack of response to high‑dose antihistamines for diagnostic support.

Clinically, the goal of acute therapy is to minimize morbidity and prevent mortality from ongoing HAE attacks; guidelines recommend that patients have ready access to effective on‑demand medication for all attacks. For HAE‑nC1INH, diagnosis is more challenging because validated biochemical tests are lacking; genetic testing for known variants (for example, F12, PLG, ANGPT1, KNG1, MYOF, HS3OST6) or a documented family history and failure of high‑dose antihistamines may help establish the diagnosis and guide on‑demand treatment decisions.

Defined Terms

Definitions

HAE type I/IIHereditary angioedema due to C1 inhibitor deficiency characterized by low C4 and low C1-INH antigenic or functional levels.

HAE-nC1INH (type III)Hereditary angioedema with normal C1-INH levels and function; diagnosis may require genetic testing or family history and documented lack of response to high-dose antihistamines.

Policy Updates

2026-01-01clarifiedLatest

Updated policy title to 'Hereditary Angioedema - C1 Esterase Inhibitors (Intravenous)' and revised documentation and specialist prescriber language as part of annual revisions.

2025-01-15annual revision

Annual revision noted with no criteria changes and updates to documentation requirements and preferred product requirements for certain plan types.

Policy Summary

PayerCigna

PolicyHereditary Angioedema - C1 Esterase Inhibitors (Intravenous)

Policy CodePolicy IP0315

Change TypeClarified wording and documentation

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

Medication is prescribed by or in consultation with an allergist/immunologist or HAE specialist

Preferred product criteria is met for the product(s) as listed in the table (for Berinert only)

[see employer/IFP section for Ruconest preference exceptions]

Patient who has treated previous acute HAE attacks with Berinert or Cinryze

Patient has a diagnosis of HAE type I or type II
[documentation required]
Prescriber reports favorable clinical response with Berinert or Cinryze (e.g., quicker symptom relief, decreased duration/severity/frequency)
Medication is prescribed by or in consultation with an allergist/immunologist or HAE specialist

Dosing

Approve 20 IU/kg, administered intravenously no more frequently than once daily.

Operational notes: If patient is currently receiving therapy but lacks prior approval, review under initial therapy criteria. Prior authorization required; documentation required for labs and response.

Medication is prescribed by, or in consultation with, an allergist/immunologist

Patient who has treated previous acute HAE attacks with Ruconest

Patient has a diagnosis of HAE type I or type II
[documentation required]
Prescriber reports favorable clinical response with Ruconest
Medication is prescribed by or in consultation with an allergist/immunologist or HAE specialist

Dosing

Approve up to a maximum dose of 4,200 units (not exceeding 50 units/kg), administered intravenously no more frequently than twice daily.

Operational note: Prior authorization required; documentation required for baseline labs and clinical response. Note that employer/IFP preferred-product rules may affect Berinert vs Ruconest selection.

Genetic/family criteria (one of)

Confirmed pathogenic variant in one of: F12, PLG, ANGPT1, KNG1, MYOF, HS3OST6
[documentation required]
If pathogenic variant not identified
- No pathogenic variant identified
  [documentation required]
- ANY of the following
  - Known family history of HAE with normal C1-INH
  - Family history of recurrent angioedema without hives

Medication prescribed by or in consultation with an allergist/immunologist or HAE specialist

Patient who has treated previous acute HAE-nC1INH attacks with Berinert or Cinryze

Patient has diagnosis of HAE with normal C1-INH
[documentation required]
Prescriber reports favorable clinical response with product
Medication prescribed by or in consultation with an allergist/immunologist or HAE specialist

Dosing

Approve 20 IU/kg, administered intravenously no more frequently than once daily.

Operational note: Documentation of labs and genetic testing or family history required; high-dose antihistamine trial must be documented. Specialist prescribing or consultation required.